Torna all'elenco degli studi

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

CODICE STUDIO

NCT06208150

TIPOLOGIA

Ricaduti

NOME SPONSOR

Janssen Reasearch&Development, LLc

DESCRIZIONE

Trattamento

Experimental: Arm A: Talquetamab + Pomalidomide (Tal-P)

Leggi tutto

FARMACI UTILIZZATI

Bortezomib (velcade), Pomalidomide, Teclistamab anticorpo bispecifico, Desametasone, Talquetamab (CAR-T)